Skip to main content

Table 3 Mutations and changes in blood samples for the 2nd and 3rd measurements

From: High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study

Variable

Category

Repeatedly measured

2nd measurement

 KRAS mutation in blood

Yes

15 (48.4)

 KRAS mutation abundance in blood (%)a

 

1.1 (0.5–6.5)

 KRAS mutation abundance in blood ≥ 5.0%

Yes

6 (19.4)

 Elevated KRAS mutation abundance in bloodb

Yes

3 (9.7)

 Change of KRAS mutation abundance in blood (%)b

 

− 1.7 (− 11.9 to − 0.3)

 Change of KRAS mutation abundance in bloodb ≤ − 2.0%

Yes

11 (35.5)

 TP53 mutation in blood

Yes

13 (41.9)

 TP53 mutation abundance in blood (%)a

 

1.2 (0.4–4.2)

 TP53 mutation abundance in blood ≥ 5.0%

Yes

3 (9.7)

 Elevated TP53mutation abundance in bloodb

Yes

2 (6.5)

 Change of TP53mutation abundance in blood (%)b

 

− 1.9 (− 6.0 to − 0.1)

 Change of TP53mutation abundance in bloodb ≤ − 2.0%

Yes

9 (29.0)

 CDKN2A mutation in blood

Yes

4 (12.9)

 CDKN2A mutation abundance in blood (%)a

 

1.5 (0.6–5.9)

 CDKN2A mutation abundance in blood ≥ 5.0%

Yes

1 (3.2)

 Elevated CDKN2A mutation abundance in bloodb

Yes

1 (3.2)

 Change of CDKN2A mutation abundance in blood (%)b

 

− 1.1 (− 5.7 to 0.0)

 Change of CDKN2A mutation abundance in bloodb ≤ − 2.0%

Yes

2 (6.5)

3rd measurement

 KRAS mutation in blood

Yes

12 (38.7)

 KRAS mutation abundance in blood (%)a

 

3.7 (1.9–10.6)

 KRAS mutation abundance in blood ≥ 5.0%

Yes

5 (16.1)

 Elevated KRAS mutation abundance in bloodb

Yes

1 (3.2)

 Change of KRAS mutation abundance in blood (%)b

 

− 1.7 (− 6.6 to − 0.8)

 Change of KRAS mutation abundance in bloodb ≤ − 2.0%

Yes

9 (29.0)

 TP53 mutation in blood

Yes

9 (29.0)

 TP53mutation abundance in blood (%)a

 

3.1 (1.5–3.6)

 TP53mutation abundance in blood ≥ 5.0%

Yes

2 (6.5)

 Elevated TP53mutation abundance in bloodb

Yes

2 (6.5)

 Change of TP53mutation abundance in blood (%)b

 

− 1.9 (− 4.7 to − 0.3)

 Change of TP53mutation abundance in bloodb ≤ − 2.0%

Yes

8 (25.8)

 CDKN2A mutation in blood

Yes

3 (9.7)

 CDKN2A mutation abundance in blood (%)a

 

4.0 (3.1–4.0)

 CDKN2A mutation abundance in blood ≥ 5.0%

Yes

0 (0.0)

 Elevated CDKN2A mutation abundance in bloodb

Yes

1 (3.2)

 Change of CDKN2A mutation abundance in blood (%)b

 

− 1.2 (− 3.5 to 0.0)

 Change of CDKN2A mutation abundance in bloodb ≤ − 2.0%

Yes

2 (6.5)

  1. aComputed for the respective gene with mutation in the respective specimen
  2. bCompared with baseline